Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 944-092-9 | CAS number: -
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Repeated dose toxicity: oral
Some information in this page has been claimed confidential.
Administrative data
- Endpoint:
- short-term repeated dose toxicity: oral
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 1991-05-08 to 1991-05-09
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- guideline study
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 1 991
- Report date:
- 1991
Materials and methods
Test guideline
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 407 (Repeated Dose 28-Day Oral Toxicity Study in Rodents)
- Deviations:
- no
- GLP compliance:
- yes (incl. QA statement)
- Limit test:
- no
Test material
- Test material form:
- solid: particulate/powder
- Details on test material:
- Direct Red 83:1
Constituent 1
Test animals
- Species:
- rat
- Strain:
- Sprague-Dawley
- Details on species / strain selection:
- The rat was selected for this study as it is a readily available rodent species historically used in safety evaluation studier and is acceptable to appropriate regulatory authorities.
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: Sprague-Dawley CD Strain rats
- Age at study initiation: 5 to 8 weeks
- Weight at study initiation: will not exceed ±20% of the mean weight.
- Fasting period before study:
- Housing: Groups of five by sex in polypropylene cages with stainless steel lids and grid bases suspended over trays containing absorbent paper.
- Diet (e.g. ad libitum): ad libitum
- Water (e.g. ad libitum): ad libitum
- Acclimation period: 5 days
ENVIRONMENTAL CONDITIONS
- Temperature (°C):19-25
- Humidity (%):40-75
- Air changes (per hr): at least 15 air changes/h
- Photoperiod (hrs dark / hrs light): 12 hours of continuous artificial light in each 24 hours period.
IN-LIFE DATES: From: 1991-05-08 to 1991-05-09
Administration / exposure
- Route of administration:
- oral: gavage
- Details on route of administration:
- The oral route was selected as a possible route of human exposure and the results of the study are believed to be of value in predicting the likely toxicity of the test material to man.
- Vehicle:
- water
- Remarks:
- Distilled water
- Details on oral exposure:
- PREPARATION OF DOSING SOLUTIONS:
The test material was prepared at the appropriate concentrations, as a solution/suspension in distilled water.
The stability and homogeneity of the test material formulations were determined and show the formulation to be stable for at least 9 days.
Formulations were therefore prepared weekly and stored at 4°C in the dark. - Analytical verification of doses or concentrations:
- yes
- Details on analytical verification of doses or concentrations:
- Samples were taken of each test material formulation and were analysed for concentration of Direct Red 83:1 using aspectrophotometric procedure.
The results indicate that the prepared formulations were within ± 10% of the nominal concentration. - Duration of treatment / exposure:
- 28 days
- Frequency of treatment:
- Daily
Doses / concentrationsopen allclose all
- Dose / conc.:
- 1 000 mg/kg bw/day (nominal)
- Remarks:
- The dose levels were chosen based an the results of a range-finding study.
- Dose / conc.:
- 150 mg/kg bw/day (nominal)
- Dose / conc.:
- 15 mg/kg bw/day (nominal)
- No. of animals per sex per dose:
- 5 males/5 females
- Control animals:
- yes, concurrent vehicle
- Details on study design:
- - Dose selection rationale:
The dose levels were chosen based an the results of a range-finding study.
- Rationale for animal assignment (if not random): random
- Fasting period before blood sampling for clinical biochemistry: Animals were not fasted prior to sampling.
- Rationale for selecting satellite groups: NA - Positive control:
- not required
Examinations
- Observations and examinations performed and frequency:
- CAGE SIDE OBSERVATIONS: Yes
DETAILED CLINICAL OBSERVATIONS: Yes
- Time schedule: daily
BODY WEIGHT: Yes Individual bodyweights recorded on the day before the start of dosing (day 0) and at weekly intervals thereafter.
- Time schedule for examinations: 0 day to weekly interval
FOOD CONSUMPTION: Diet intake recorded weekly for each cage group.
WATER CONSUMPTION: Yes, monitored daily by visual inspection of water bottles. Measurement will be initiated, if a treatment related effect is suspected, at the discretion of the study director.
- Time schedule for examinations: daily
HAEMATOLOGY: Yes
- Time schedule for collection of blood: At the end of the treatment period
- Anaesthetic used for blood collection: Yes (identity) Halothane B.P. anesthesia
- Animals fasted: No data
- How many animals: all animals from group 1 to 4
URINALYSIS: Yes
Urine samples collected from all animals in groups 1 to 4 during the final week of the study by housing overnight in metabolism cages under normal hydration but without access to food. Urinalysis will be performed on satellite group animals where abnormalities are detected in the main study. - Sacrifice and pathology:
- HISTOPATHOLOGY: Initially the following tissues were examined microscopically from:
a) all animals that die during the study
b) all animals in the control and high dose groups (group 1 and 4)
Heart Adrenals
Liver Target organ
Spleen Gross lesions
Kidneys Testes
These examinations were extended to animals of other dose groups including satellite groups. - Other examinations:
- Hematological, blood chemical and organ weight data will be assessed using one way analysis of variance incorporating "F-max"
- Statistics:
- Variance incorporating "F-max" test for homogeneity variance.
The organ weights will be expressed as percentage of final bodyweight. Other statistical analyses such as students "t" test, analysis of covariance, Kruskal-Wallis analysis and Mann-Whitney "u" test may be performed if necessary.
Results and discussion
Results of examinations
- Clinical signs:
- no effects observed
- Description (incidence and severity):
- There were no treatment-related deaths during the study although one high dose male died during the blood sampling procedure.
- Mortality:
- no mortality observed
- Description (incidence):
- There were no treatment-related deaths during the study although one high dose male died during the blood sampling procedure.
- Body weight and weight changes:
- no effects observed
- Description (incidence and severity):
- Bodyweight gains in test animal were comparable with those seen in controls.
- Food consumption and compound intake (if feeding study):
- no effects observed
- Description (incidence and severity):
- No adverse effect on food consumption or weekly food efficiency was detected during the study.
- Food efficiency:
- no effects observed
- Description (incidence and severity):
- No adverse effect on weekly food efficiency was detected during the study.
- Water consumption and compound intake (if drinking water study):
- no effects observed
- Description (incidence and severity):
- No overt intergroup differences were detected.
- Ophthalmological findings:
- not examined
- Description (incidence and severity):
- No data avalaible
- Haematological findings:
- no effects observed
- Description (incidence and severity):
- No treatment-related effects were detected
- Clinical biochemistry findings:
- no effects observed
- Description (incidence and severity):
- No treatment-related effect were detected
- Urinalysis findings:
- no effects observed
- Description (incidence and severity):
- No treatment-related effect were detected
- Organ weight findings including organ / body weight ratios:
- no effects observed
- Description (incidence and severity):
- No treatment-related effect were detected
- Histopathological findings: non-neoplastic:
- no effects observed
- Description (incidence and severity):
- No treatment-related effects were detected
- Histopathological findings: neoplastic:
- not examined
- Description (incidence and severity):
- not applicable
- Details on results:
- CLINICAL SIGNS AND MORTALITY No clinically observable signs of toxicity were detected in test or control animals throughout the study period.
BODY WEIGHT AND WEIGHT GAIN: Bodyweight gains in test animals were comparable with those seen in controls.
FOOD CONSUMPTION AND COMPOUND INTAKE (if feeding study) No adverse effect on food consumption.
FOOD EFFICIENCY: no weekly food efficiency was detected during the study.
WATER CONSUMPTION AND COMPOUND INTAKE (if drinking water study): No overt intergroup differences were detected.
HAEMATOLOGY No treatment-related effects were detected
CLINICAL CHEMISTRY: No treatment-related effects were detected
URINALYSIS: No treatment-related effects were detected
NEUROBEHAVIOUR: no data available
ORGAN WEIGHTS: No treatment-related effects were detected
HISTOPATHOLOGY: NON-NEOPLASTIC: No treatment-related effects were detected
OTHER FINDINGS
Necropsy: No treatment-related effects were detected.
Effect levels
- Key result
- Dose descriptor:
- NOEL
- Effect level:
- 1 000 mg/kg bw/day (actual dose received)
- Based on:
- test mat.
- Sex:
- male/female
- Remarks on result:
- not determinable due to absence of adverse toxic effects
Target system / organ toxicity
- Critical effects observed:
- no
Any other information on results incl. tables
Week Food efficiency * -Females
Group number | Dose level (mg/kg/day) | Food efficiency during Week 1 2 3 4 | |||
1 | 0 (control) | 0.22 | 0.19 | 0.13 | 0.10 |
2 | 15 | 0.22 | 0.19 | 0.14 | 0.12 |
3 | 150 | 0.26 | 0.18 | 0.11 | 0.11 |
4 | 1000 | 0.22 | 0.20 | 0.12 | 0.08 |
*Food Efficiency= Change in Mean Bodyweight (g) / Food consumption (g/rat/week)
Week Food efficiency -Males
Group number | Dose level (mg/kg/day) | Food efficiency during Week 1 2 3 4 | |||
1 | 0 (control) | 0.31 | 0.26 | 0.22 | 0.13 |
2 | 15 | 0.31 | 0.27 | 0.21 | 0.15 |
3 | 150 | 0.32 | 0.27 | 0.22 | 0.17 |
4 | 1000 | 0.32 | 0.27 | 0.21 | 0.16 |
Homogeneity of test material formulations
Nominal concentration (mg/L) | Sampling location | Concentration found (mg/mL)1 2 3 Mean | |||
1 | Top Middle Bottom | 0.831 0.842 0.840 | 0.847 0.830 0.849 | 0.853 0.855 0.853 | 0.844 0.842 0.847 |
5 | Top Middle Bottom | 4.48 4.45 4.44 | 4.44 4.50 4.52 | 4.52 4.55 4.56 | 4.48 4.50 4.51 |
25 | Top Middle Bottom | 23.0 23.2 23.3 | 23.1 22.4 22.9 | 23.1 23.3 22.5 | 23.1 23.0 22.9 |
100 | Top Middle Bottom | 92.8 92.9 91.6 | 94.2 91.4 92.2 | 93.6 92.9 93.0 | 93.5 92.4 92.3 |
Stability of test material formulations
Nominal concentration (mg/L) | Concentration found initially | Concentration found after Storage for 9 days(mg/mL) (expressed as % of initial) | |||
1 | 0.844 | 0.872 | 103 | ||
5 | 4.50 | 4.46 | 99 | ||
25 | 23.0 | 22.8 | 99 | ||
100 | 92.7 | 90.8 | 98 |
Applicant's summary and conclusion
- Conclusions:
- Oral administration of the test material to rats for a period of twenty-eight consecutive days by gavage, at dose levels of up to 1000 mg/kg/day did not result in any toxicologically significant changes. The no observed effect level (NOEL) is, therefore, considered to be 1000 mg/kg/day.
- Executive summary:
Oral administration of the test material to rats for a period of twenty-eight consecutive days by gavage, at dose levels of up to 1000 mg/kg/day did not result in any toxicologically significant changes. The no observed effect level (NOEL) is, therefore, considered to be 1000 mg/kg/day.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
Welcome to the ECHA website. This site is not fully supported in Internet Explorer 7 (and earlier versions). Please upgrade your Internet Explorer to a newer version.
This website uses cookies to ensure you get the best experience on our websites.
Find out more on how we use cookies.